Cargando…
Clinical and immunohistochemical study of eight cases with thymic carcinoma
BACKGROUND: Thymic carcinoma is a rare neoplasm with extremely poor prognosis. To evaluate the biological characteristics of thymic carcinoma, we reviewed 8 patients. METHODS: There were 2 men and 6 women: ages ranged from 19 to 67 years old (mean 54.8 years). None of these patients had concomitant...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC115847/ https://www.ncbi.nlm.nih.gov/pubmed/12049674 http://dx.doi.org/10.1186/1471-2482-2-3 |
_version_ | 1782120251905802240 |
---|---|
author | Tomita, Masaki Matsuzaki, Yasunori Edagawa, Masao Maeda, Masayuki Shimizu, Tetsuya Hara, Masaki Onitsuka, Toshio |
author_facet | Tomita, Masaki Matsuzaki, Yasunori Edagawa, Masao Maeda, Masayuki Shimizu, Tetsuya Hara, Masaki Onitsuka, Toshio |
author_sort | Tomita, Masaki |
collection | PubMed |
description | BACKGROUND: Thymic carcinoma is a rare neoplasm with extremely poor prognosis. To evaluate the biological characteristics of thymic carcinoma, we reviewed 8 patients. METHODS: There were 2 men and 6 women: ages ranged from 19 to 67 years old (mean 54.8 years). None of these patients had concomitant myasthenia gravis and pure red cell aplasia. No patient had stage I disease, 1 stage II, 5 stage III, and 2 stage IV. The pathologic subtypes of thymic carcinoma included 5 squamous cell carcinomas, 1 adenosquamous cell carcinomas, 1 clear cell carcinoma, and 1 small cell carcinoma. Immunohistochemical study was performed using antibodies against p53, bcl-2, Ki-67, carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA), nm23-H1, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF-2) and factor VIII. RESULTS: Curative resection could be done in 4 patients (50%). Our data indicates a trend toward an association between complete resection and patient survival. Expression of p53, bcl-2, CEA, EMA, nm23-H1, VEGF and FGF-2 was detected in 5/8, 3/8, 4/8, 5/8, 6/8, 5/8 and 3/8, respectively. Mean Ki-67 labeling index and microvessel density was 7.01 and 34.36 (per 200× field), respectively. When compared with our previous studies, immunohistochemical staining of these proteins in thymomas, the expression rates of these proteins in thymic carcinomas were higher than those in thymomas. CONCLUSIONS: In this small series, it is suggested that a complete resection suggests a favorable result. Immunohistochemical results reveal that the expression of these proteins might indicate the aggressiveness of thymic carcinoma. |
format | Text |
id | pubmed-115847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1158472002-06-14 Clinical and immunohistochemical study of eight cases with thymic carcinoma Tomita, Masaki Matsuzaki, Yasunori Edagawa, Masao Maeda, Masayuki Shimizu, Tetsuya Hara, Masaki Onitsuka, Toshio BMC Surg Research Article BACKGROUND: Thymic carcinoma is a rare neoplasm with extremely poor prognosis. To evaluate the biological characteristics of thymic carcinoma, we reviewed 8 patients. METHODS: There were 2 men and 6 women: ages ranged from 19 to 67 years old (mean 54.8 years). None of these patients had concomitant myasthenia gravis and pure red cell aplasia. No patient had stage I disease, 1 stage II, 5 stage III, and 2 stage IV. The pathologic subtypes of thymic carcinoma included 5 squamous cell carcinomas, 1 adenosquamous cell carcinomas, 1 clear cell carcinoma, and 1 small cell carcinoma. Immunohistochemical study was performed using antibodies against p53, bcl-2, Ki-67, carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA), nm23-H1, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF-2) and factor VIII. RESULTS: Curative resection could be done in 4 patients (50%). Our data indicates a trend toward an association between complete resection and patient survival. Expression of p53, bcl-2, CEA, EMA, nm23-H1, VEGF and FGF-2 was detected in 5/8, 3/8, 4/8, 5/8, 6/8, 5/8 and 3/8, respectively. Mean Ki-67 labeling index and microvessel density was 7.01 and 34.36 (per 200× field), respectively. When compared with our previous studies, immunohistochemical staining of these proteins in thymomas, the expression rates of these proteins in thymic carcinomas were higher than those in thymomas. CONCLUSIONS: In this small series, it is suggested that a complete resection suggests a favorable result. Immunohistochemical results reveal that the expression of these proteins might indicate the aggressiveness of thymic carcinoma. BioMed Central 2002-05-23 /pmc/articles/PMC115847/ /pubmed/12049674 http://dx.doi.org/10.1186/1471-2482-2-3 Text en Copyright © 2002 Tomita et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Research Article Tomita, Masaki Matsuzaki, Yasunori Edagawa, Masao Maeda, Masayuki Shimizu, Tetsuya Hara, Masaki Onitsuka, Toshio Clinical and immunohistochemical study of eight cases with thymic carcinoma |
title | Clinical and immunohistochemical study of eight cases with thymic carcinoma |
title_full | Clinical and immunohistochemical study of eight cases with thymic carcinoma |
title_fullStr | Clinical and immunohistochemical study of eight cases with thymic carcinoma |
title_full_unstemmed | Clinical and immunohistochemical study of eight cases with thymic carcinoma |
title_short | Clinical and immunohistochemical study of eight cases with thymic carcinoma |
title_sort | clinical and immunohistochemical study of eight cases with thymic carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC115847/ https://www.ncbi.nlm.nih.gov/pubmed/12049674 http://dx.doi.org/10.1186/1471-2482-2-3 |
work_keys_str_mv | AT tomitamasaki clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma AT matsuzakiyasunori clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma AT edagawamasao clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma AT maedamasayuki clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma AT shimizutetsuya clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma AT haramasaki clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma AT onitsukatoshio clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma |